Preclinical and clinical studies of breast cancer prevention with transdermal anti-progesterone agents

Project: Research project

Project Details


We have proposed to test the efficacy of combination therapy of a progesterone receptor (PR) modulator ulipristal acetate (UPA) and a selective COX-2 inhibitor (Celecoxib) for prevention of Brca1 deficient mammary tumorigenesis in a mouse model. In this 2nd year, we will continue on this theme. We have actively cross-bred to build the experimental cohort with Ad-K8-Cre Brca1f22-24/f22-24; Trp53f2-10/f2-10; R26Y mice (named as BPY mice) to test drug efficacy and expect randomization to the treatment in August.
Effective start/end date10/1/219/30/22


  • Breast Cancer Research Foundation (BCRF-21-087)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.